CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

People who use popular diabetes drugs called GLP-1 receptor agonists may be at  increased risk for a serious eye disease, a ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

Published in Cell Metabolism, the Phenomix and Mayo Clinic research shows the MyPhenome™ test can help providers guide ...

Based on Caliway's preclinical data, co-administration of CBL-514 with GLP-1 significantly reduced post-discontinuation body weight regain and fat replenishment rate — suggesting that CBL-514 may help ...

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

GLP-1 receptor agonists may aid smoking cessation by curbing cravings and mitigating weight gain, which often are impediments ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...